[1] Ding L, Yang L, Wang Z, Huang W, et al. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B, 2015,5(2): 135-144.
[2] Gabler M, Kramer J, Schmidt J,et al.Allosteric modulation of the farnesoid X receptor by a small molecule. Sci Rep, 2018,8(1):6846.
[3] Wong VW.Current prevention and treatment options for NAFLD. Adv Exp Med Biol, 2018,1061:149-157.
[4] Shin DJ, Wang L. Bile acid-activated receptors: a review on FXR and other nuclear receptors.Handb Exp Pharmacol,2019,256:51-72.
[5] Sagar NM, McFarlane M, Nwokolo C, et al.Mechanisms of triglyceride metabolism in patients with bile acid diarrhea. World J Gastroenterol, 2016,22(30):6757-6763.
[6] Kim T, Nason S, Holleman C, et al. Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21.Diabetes,2018,67(9):1773-1782.
[7] Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial. Lancet,2018,391(10126):1174-1185.
[8] Brunt EM, Kleiner DE, Wilson LA, et al. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis research network treatment trials. Hepatology,2019,70(2):522-531.
[9] Fiorucci S, Biagioli M, Zampella A, et al.Bile acids activated receptors regulate innate immunity. Front Immunol, 2018,9:1853.
[10] Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology, 2015,148(4):751-761.e8.
[11] 陈科全, 周碧瑶,陈雅莹,等.法尼酯衍生物X受体活化对肝星状细胞TIMP-1、TIMP-2及MMP-2表达的调节作用. 临床肝胆病杂志, 2013,29(04): 290-293.
[12] Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol,2018,24(2):195-210.
[13] Hodge RJ, Nunez DJ. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype? Diabetes Obes Metab, 2016,18(5):439-443.
[14] Xin XM, Zhong MX, Yang GL, et al. GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. World J Gastroenterol, 2014,20(42):15727-15735.
[15] Eaton JE, Vuppalanchi R, Reddy R, et al. Liver injury in patients with cholestatic liver disease treated with obeticholic acid. Hepatology,2020,71(4):1511-1514.
[16] Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with NASH: a phase 2 randomized controlled trial. Hepatology,2020,72(1):58-71.
[17] Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicenter, randomized, placebo-controlled phase 3 trial. Lancet,2019,394(10215):2184-2196.
[18] Tully DC, Rucker PV, Chianelli D, et al. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem,2017,60(24):9960-9973.
[19] Badman MK, Chen J, Desai S, et al.Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers. Clin Pharmacol Drug Dev, 2020,9(3):395-410.
[20] Carino A, Biagioli M, Marchianò S,et al.Disruption of TFGbeta-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacol Res, 2018,131:17-31. |
